U.S. FDA panel: data support safety, efficacy of Merck allergy drug

[riky]

U.S. FDA panel: data support safety, efficacy of Merck allergy drug

(Reuters) - Merck & Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday. About 30 million people in the United States suffer allergies to ragweed pollen, according to the FDA. However, Morningstar analyst Damien Conover believes sales could reach as much as $1 billion if enough allergy sufferers prefer Ragwitek, a pill, to injections. The pill, which is comprised of extracts from short ragweed pollen, would be taken daily beginning 12 weeks prior to the start of the ragweed pollen season and throughout the season.

Source: You are not allowed to view links. Register or Login